https://www.prnewswire.com/apac/news-releases/alphamab-oncology-announced-anti-her2-bispecific-adc-jskn003-received-approval-from-cde-to-initiate-a-phase-iii-clinical-study-for-ovarian-cancer-302340070.html
Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate...
/PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from...